Meeting
2011 ASCO Annual Meeting
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes.
Authors
P. Laneuville
McGill University Health Center, Royal Victoria Hospital, Montreal, QC, Canada
P. Laneuville , M. Baccarani , J. E. Cortes , A. Hochhaus , H. Kantarjian , N. P. Shah , M. B. Bradley-Garelik , C. Zhu , K. Porkka
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00481247
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6605)
Abstract #
6605
Poster Bd #
39B
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Impact of dose reductions on 5-year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) from DASISION.
First Author: Jorge E. Cortes
Poster
2011 ASCO Annual Meeting
Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Two-year follow-up from DASISION.
First Author: H. Kantarjian
Poster
2014 ASCO Annual Meeting
Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison.
First Author: Belal Firwana
Poster
2021 ASCO Annual Meeting
The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.
First Author: Tim H. Brümmendorf